• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Precision Medicine Oncology | Molecular Profiling | News, Analysis, Insights

Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology

by Fred Pennic 05/02/2019 Leave a Comment

Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology

 Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More

ICON Acquires Precision Medicine for Oncology Company MolecularMD

by Fred Pennic 02/21/2019 Leave a Comment

ICON Acquires Precision Medicine for Oncology Company MolecularMD

ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More

Proteus Launches Digital Cancer Chemotherapy Pill Program for Cancer Patients

by Jasmine Pennic 01/18/2019 Leave a Comment

Proteus Digital Health

Proteus Digital Health, Inc., Fairview Health Services, and the University of Minnesota Health announced that for the first time cancer patients are using digital oncology medicines to support treatment regimens and improve outcomes. This advancement helps patients complete oral chemotherapy cycles while oncologists gain new insights into their patients’ treatment progress and overall health status. Proteus, Fairview, and the University of Minnesota Health unveiled the care model for digital
Read More

Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care

by Jasmine Pennic 11/01/2018 Leave a Comment

Google Cancer Research

New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care. The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. For Syapse, the data contained in theNCCN Biomarkers Compendium will
Read More

Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis

by Jasmine Pennic 09/26/2018 Leave a Comment

Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis

Proscia, a Philadelphia-based digital pathology platform has raised $8.3 million in Series A funding led by Boston-based Flybridge Capital Partners with participation from Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, and RobinHood Ventures.The startup plans to utilize the Series A funding to fuel the development and commercialization of new, clinical AI-enabled workflows targeting high-volume, high-impact cancers, the first of which will be available later this year. In
Read More

Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

by Jasmine Pennic 06/19/2018 Leave a Comment

Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in
Read More

Syapse Precision Medicine Council Launches to Advance Precision Oncology Adoption

by Fred Pennic 06/08/2018 Leave a Comment

Syapse_Syapse Forms Precision Medicine Council to Advance Precision Oncology Adoption

Syapse, a San Francisco, CA-based precision medicine company, announced today the formation of the Syapse Precision Medicine Council, a group of oncology, operations, and research leaders from health systems dedicated to advancing precision oncology adoption through sharing best practices.Inaugural members include Henry Ford Health System, Catholic Health Initiatives and Dignity Health (the Precision Medicine Alliance), Providence St. Joseph Health, Aurora Health Care, and the University of
Read More

Fitango Health Unveils Oncology Precision Medicine App for Providers to Achieve Value-Based Goals

by Jasmine Pennic 06/01/2018 Leave a Comment

Fitango Health, a provider of integrated care management and patient engagement software, is announcing a transformative new solution, called Fitango Oncology.  Fitango Health's innovative application allows healthcare providers to achieve value-based goals through end-to-end engagement spanning the continuum of care.This end-to-end solution is the first of its kind for both oncology and chronic care to integrate decision-support, treatment communication, along with enabling and engaging both
Read More

Precision Health AI Launches Oncology AI Platform Driven by EMR Dataset

by HITC Staff 03/01/2018 Leave a Comment

Precision Health AI Launches Oncology AI Platform Driven by EMR Dataset

Precision Health AI, a healthcare technology company focused on the application of artificial intelligence to cancer care, today announced the launch of the Eureka Health Oncology AI Platform. The 60+ set of pre-trained AI solution modules will utilize Precision Health AI’s proprietary data to predict a patient’s cancer stage, treatment journey, flow through the healthcare system and survival rate.Driving the new Eureka Health Oncology AI platform is Precision Health AI’s deep, longitudinal
Read More

Medidata, Syapse Partner to Democratize Access to Oncology Clinical Trials

by Fred Pennic 02/01/2018 Leave a Comment

Syapse_Syapse Forms Precision Medicine Council to Advance Precision Oncology Adoption

Medidata, a provider of cloud-based technology and data analytics for clinical research, and Syapse, a precision medicine solutions provider, have announced a new partnership to transform oncology clinical trials for the age of precision medicine. As part of the new partnership, Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials,Partnership DetailsThe partnership will initially build products
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |